NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the benefits of NGS in oncology.
- Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and others highlight the importance of NGS in treatment planning.
- Additional experts, such as Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Roboz, MD, contribute to the discussion.
No direct quotes are available in the provided text.
Author's summary: NGS improves biomarker testing in solid tumors.
More News
- A Powerclown Halloween: on singing the Village People in Japanese, Scum Element, and Shakes the Clown
- Illinois House Democrats push first-in-the-world wealth tax, streaming, concert taxes
- Landry's Explosive Quote That Signals Major Changes at LSU
- Going Places: Discovery Bicycle Tours’ Vietnam: Hoi An’s Dazzling Lights, Tranquil Countryside
- Will today’s Fed rate cut be last one until summer 2026? - Sharecafe
- Oncology Insights with Petros Grivas - Episode 1
- Black artists music wouldn't be the same without | News Channel 3-12
- Shinzo Abe Killer’s Trial Is Exposing the Christian Cult Entrenched in Japanese Politics